New Virus-Immunotherapy combo tackles Hard-to-Treat cancers
NCT ID NCT07154108
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new approach for people with recurrent or metastatic head/neck cancer or esophageal cancer. The treatment combines a virus that delivers endostatin directly into tumors with an immunotherapy drug (PD-1 inhibitor). The goal is to see if the combination is safe and can shrink tumors. About 40 participants will be enrolled across two groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human endostatin adenovirus (a virus that delivers endostatin to tumors) plus a PD-1 inhibitor (immunotherapy)
What this could lead to
If this works, it could point toward a new combination treatment for advanced head/neck and esophageal cancers that have stopped responding to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 40 people, so it is primarily testing safety. The combination may not shrink tumors or may cause serious side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••